Picking the Lane You’re Going to Win In

Four soft-tissue surgical robotics companies filled out the 2026 challenger field, and each one picked a different lane to enter against the incumbent. Medtronic led with urology at academic medical centers. Johnson & Johnson built a platform around space-constrained ORs the incumbent could not reach. CMR Surgical waited a year for gen-two hardware rather than enter with gen-one. Intuitive kept accelerating across the same window. Same category, same incumbent, four different bets. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go — those are the problems The Build exists to help you think through, and the most useful structural question that runs through all of them is the one a competing founder has to answer before the engineering team is sized, the trial is designed, or the launch is planned. Which lane are you actually going to win in?

Every Category Has More Lanes Than the Headline Suggests

The default first-time founder reads a category dominated by an incumbent and frames the build around a single lane: a better version of what the incumbent already sells. The build-phase logic is that the incumbent is already executing on the category, that the addressable demand is whatever sits inside the incumbent’s footprint, and that the competitive question is feature parity plus a price or service angle. The cost of the single-lane read is that the company arrives at the buyer-side conversation competing for the customer the incumbent already serves, on the terms the incumbent already set, against the next-generation reference standard the incumbent is already shipping. The win-rate inside that lane is structurally low, because the incumbent has the channel, the brand, the install base, and the upgrade path on the same product the company is trying to displace.

The version of the category read that produces a credible competing business is the one that maps the lanes inside the category before the engineering work begins. Indication or use-case sequencing is one lane. Form-factor or deployment-environment differentiation is a second. Generation-quality discipline (waiting until the platform earns the right to enter against the current-generation reference standard) is a third. Channel or geography sequencing is a fourth. Buyer-segment positioning (the underserved segment inside the incumbent’s addressable base) is a fifth. Each lane has a different evidence requirement, a different reference-customer base, a different commercial sequence, and a different participation profile the buyer side reads. The founder’s structural job is to pick the lane the company can credibly win in, then design the business to win in that lane rather than across all of them.

The four 2026 surgical robotics challengers are the cleanest current example of multi-lane competition inside a single category. None of them chose to compete on feature parity against the incumbent’s next-generation reference standard. Each chose a different lane that the incumbent was structurally less able to compete in immediately. The architectural decision came first inside each company. The engineering work, the trial design, and the commercial sequence were all built against the chosen lane. The category looks crowded from the outside, but the actual head-to-head competition inside any given lane is much narrower than the headline suggests, because each challenger is competing in a different one.

How to Read the Lanes Inside Your Category

Reading the lanes inside your category is a research and synthesis discipline, and it compounds through the build phase into the operating-plan resilience the buyer side reads at the deal-stage moment. The founders who run the discipline well start by mapping the incumbent’s addressable base across its own internal segmentation. What indications does the incumbent serve, in what sequence, with what evidence base? What deployment environments does the incumbent ship into, and which ones is the incumbent structurally unable to enter (because of form factor, capital intensity, channel structure, or installed-base inertia)? What buyer segments inside the addressable base does the incumbent under-serve relative to the average? What geographic markets has the incumbent under-prioritized relative to the global opportunity? Each lane that emerges from the map is a candidate position the company could compete from, and each lane has a different evidence requirement, a different commercial cost structure, and a different time-to-revenue profile.

At the operating level, the discipline produces a lane map that the business runs the architectural, financial, and operating decisions against. The map identifies the specific lane the company is going to compete from, the evidence base required to win in that lane, the reference-customer profile the lane is anchored on, and the commercial cost structure the operating plan has to support. The companies that finish in multi-lane categories pick a single lane and execute against it with discipline through the build phase. The companies that stall pick multiple lanes implicitly, accumulate trial designs and engineering features that point in different directions, and arrive at launch with a positioning the buyer side reads as confused rather than focused. The incumbent doesn’t have to beat them on any single lane. The buyer side reads the inconsistency and chooses the focused competitor over the confused one.

Building the Operating System Around the Lane You Picked

The operating system inside a business that wins a single lane has three durable structural features. The first is an explicit, written architecture document that records the lane decision, the evidence requirement, the reference-customer profile, the commercial sequence, and the operating-plan assumptions the lane decision generated. The document lives at the top of the operating-plan stack, is reviewed at the quarterly business review, and is updated only when the underlying competitive map produces a signal that the lane is no longer the right one. The second is an engineering, regulatory or qualification, and commercial work-plan that flows from the architecture document downstream rather than upstream. The work plans inherit the architectural constraints, not the other way around. The third is a competitive-monitoring rhythm that tracks the incumbent’s movement inside the chosen lane and the chosen-lane-adjacent positions. The monitor surfaces signals when the incumbent moves into the lane or when the lane moves under the incumbent’s feet, and the architecture document updates against the signal on a quarterly review cadence.

Founders who build this operating system arrive at each buyer-side conversation, regulatory milestone, and commercial milestone with the lane decision visible, the evidence anchored against the lane, and the reference-customer base assembled to support it. Founders who defer the lane decision until launch year arrive with a positioning the buyer side reads as a parity play against the incumbent’s next-generation standard. The Build covers the structural and operating questions that produce the multi-lane competitive map and the architectural discipline that wins inside a chosen lane, in practical terms for founders running real businesses across categories. Which lanes are sitting inside your category that the incumbent is structurally unable to reach right now? Which one of those lanes does your company have the right to compete in? Which engineering, evidence, and commercial decisions does the lane require you to make, and which ones does it free you to skip? Which operating-plan assumptions are sitting on a lane your company isn’t actually going to compete in?

What the Four Surgical Robotics Challengers Show in Practice

Medtronic competes on indication sequencing and commercial-engine scale. The lane is the full soft-tissue procedure base across the next 24 to 36 months, anchored on academic-medical-center reference customers, with urology as the entry indication and gynecology and general surgery staged behind already-run pivotal trials. Johnson & Johnson competes on form-factor differentiation and addressable-OR expansion. The lane is the hospital and ASC inventory of space-constrained ORs the incumbent platform cannot operate in, with bariatric surgery as the pivotal-trial proving ground. CMR Surgical competes on operational discipline and platform-quality positioning. The lane is the US soft-tissue entry against the incumbent’s current-generation reference standard, earned through a deliberate 12-to-18-month delay to ship gen-two rather than gen-one. Each lane is a defensible position that the chosen architecture is built to win. None of them is competing in the same lane as the others, and none of them is competing in the lane Intuitive is currently sitting in. The architectural discipline is the structural input. The engineering, the evidence, and the commercial sequence are downstream from the lane decision.